

## **I3 - Immunologie-immunopathologie-immunothérapie**

Rapport Hcéres

► **To cite this version:**

Rapport d'évaluation d'une entité de recherche. I3 - Immunologie-immunopathologie-immunothérapie. 2018, Université Pierre et Marie Curie - UPMC, Institut national de la santé et de la recherche médicale - INSERM. hceres-02030999

**HAL Id: hceres-02030999**

**<https://hal-hceres.archives-ouvertes.fr/hceres-02030999>**

Submitted on 20 Feb 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

REPORT ON THE RESEARCH UNIT:  
Immunologie - Immunopathologie -  
Immunothérapie (i<sup>3</sup>)

UNDER THE SUPERVISION OF THE  
FOLLOWING INSTITUTIONS AND  
RESEARCH BODIES:

Université Pierre et Marie Curie  
Institut National de la Santé et de la Recherche  
Médicale - INSERM

**ÉVALUATION CAMPAIGN 2017-2018**  
GROUP D



In the name of Hcéres<sup>1</sup> :

Michel Cosnard, President

In the name of the experts committees<sup>2</sup> :

Camille Loch, Chairman of the committee

Under the decree No.2014-1365 dated 14 november 2014,

<sup>1</sup> The president of HCERES "countersigns the evaluation reports set up by the experts committees and signed by their chairman." (Article 8, paragraph 5);

<sup>2</sup> The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2).

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

## UNIT PRESENTATION

<b>Unit name:</b>	Immunologie - Immunopathologie – Immunothérapie
<b>Unit acronym:</b>	i <sup>3</sup>
<b>Requested label:</b>	UMR
<b>Application type:</b>	Renewal
<b>Current number:</b>	959
<b>Head of the unit (2017-2018):</b>	Mr David KLATZMANN
<b>Project leader (2019-2023):</b>	Mr David KLATZMANN
<b>Number themes:</b>	3

## COMMITTEE MEMBERS

<b>Chair:</b>	Mr Camille LOCHT, Institut Pasteur de Lille
<b>Experts:</b>	Mr Lionel APETOH, Université de Bourgogne Franche Comté (representative of INSERM CSS) Mr Amar BENNASROUNE, Université de Reims Champagne-Ardenne (representative of CNU) Mr Onur BOYMAN, University of Zurich, Suisse Ms Jocelyne DEMENGEOT, Instituto Gulbenkian de Ciência, Portugal Mr Nicolas SETTERBLAD, Institut Universitaire d'Hématologie (supporting personnel)

### HCERES scientific officer:

Ms Sophie EZINE

### Representatives of supervising institutions and bodies:

Mr Serge AMSELLEM, Sorbonne Université

Ms Évelyne JOUVIN-MARCHE, Inserm

## INTRODUCTION

### HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The Immunology-Immunopathology-Immunotherapy (i<sup>3</sup>) research unit was created in 2009, as a single team research unit (UMRS 959), by Mr David KLATZMANN, dedicated to translational immunology. The i<sup>3</sup> research unit is located on the Pitié-Salpêtrière medical campus, a major University Hospital Campus in Paris, affiliated to the “Pierre and Marie Curie University” (UPMC), now part of the Sorbonne University.

### MANAGEMENT TEAM

The i<sup>3</sup> research unit is headed by Mr David KLATZMANN. Since this is a single team research unit, the function of deputy director is replaced by a steering committee.

### HCERES NOMENCLATURE

SVE3\_4 Immunologie.

### SCIENTIFIC DOMAIN

The I<sup>3</sup> research unit focused on translational immunology applied to the study of autoimmunity-related pathologies as well as inflammatory diseases, aspiring to implement systems biology to contribute to the advancement of therapies in the field of immunology, exploiting its recognized knowledge of the major role played by the Tregs (regulatory T lymphocytes).

### UNIT WORKFORCE

Unit workforce	Number 30/06/2017	Number 01/01/2019
<b>Permanent staff</b>		
Full professors and similar positions	5	7
Assistant professors and similar positions	5	5
Full time research directors (Directeurs de recherche) and similar positions	0	0
Full time research associates (Chargés de recherche) and similar positions	1	1
Other scientists (“Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.”)	0	0
High school teachers	0	0
Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	4,5	4,5
<b>TOTAL permanent staff</b>	<b>15,5</b>	<b>17,5</b>

<b>Non-permanent staff</b>		
Non-permanent professors and associate professors, including emeritus	1	
Non-permanent full time scientists, including emeritus, post-docs	3	
Non-permanent supporting personnel	11	
PhD Students	25	
<b>TOTAL non-permanent staff</b>	<b>40</b>	
<b>TOTAL unit</b>	<b>55,5</b>	

## GLOBAL ASSESSMENT OF THE UNIT TO BE DONE ON THE SITE VISIT

The I<sup>3</sup> Unit is one of the best-known research units in the field of auto-immune diseases in Europe and has produced research of excellent quality at the basic and translational science levels. It has pioneered the use of low-dose IL-2 (ld IL-2) in the treatment of autoimmune disease and has successfully carried out several clinical studies. To follow the recommendations of the last Hcéres report (2013), the research unit I<sup>3</sup> decided to refocus exclusively on autoimmune diseases, a topic on which the unit has made outstanding contributions.

Funding from a variety of national and international sources (including EU, ERC, NIH) has been outstanding, although essentially limited to the unit director. The unit has successfully implemented and developed novel technologies, including big data management, relying on in-house efforts and external collaborations. It also excels in integrating clinical research with mechanistic studies using appropriate animal models.



2 rue Albert Einstein  
75013 Paris, France  
T. 33 (0)1 55 55 60 10

[hceres.com](http://hceres.com)

[@Hceres\\_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)